Moving CAR-T Beyond Oncology

Sail Biomedicine’s chief products and operations officer joined the Pharmaceutical Executive Podcast to discuss how researchers are developing CAR-T therapies that go beyond oncology. According to him, recent advancements have provided researchers with significant results using CAR-T to treat autoimmune conditions, such as lupus or rheumatoid arthritis.

• Hennemand explains the historical context of cell-based therapies in oncology, noting their success but limitations due to high costs and logistical challenges.
• Hennemand explains that Sail started in oncology but quickly pivoted to autoimmune disorders due to the suitability of RNA-based CAR T therapies.
• Hennemand highlights the advantages of RNA technology, such as quick expression and fast repopulation, which make it ideal for autoimmune disorders.
• Hennemand mentions that Sail’s closest competitors also started in oncology but have since shifted their focus to autoimmune disorders.